Slides and webcasts are restricted to ESMO Members.
The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.
ESMO Virtual Plenary: November 2021
- Start date
- 19 Nov 2021
- End date
- 20 Nov 2021
This ESMO Virtual Plenary is part of the ESMO Asia Virtual Oncology Week 2021 (#ESMOasiaweek21), taking place on 17-23 November, and presenting the most important innovations in cancer research and care in 2021, highlighting Asian studies with a strong impact on the science and practice of oncology. Participation is free of charge.
Friday, 19 November 2021
12:00-13:15 CET / 19:00-20:15 SGT
Welcome and introduction, Scientific background and context
Tetsuya Mitsudomi, Kindai University Faculty of Medicine, Osaka, Japan
ORIENT-31: Phase III study of sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated nonsquamous NSCLC who progressed after EGFR-TKI therapy
Shun Lu, Shanghai Chest Hospital, Shanghai, China
Critical analysis and perspectives
Myung-Ju Ahn, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
Expert Insights Panel Discussion / Q&A
Faculty and online audience
- Chair: Tetsuya Mitsudomi, Kindai University Faculty of Medicine, Osaka, Japan
- Shun Lu, Shanghai Chest Hospital, Shanghai, China
- Myung-Ju Ahn, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
- Benjamin Besse, Gustave Roussy, Villejuif, France
- Daniel Tan, NCCS - National Cancer Centre Singapore, Singapore
Saturday, 20 November 2021
12:00-13:15 CET / 19:00-20:15 SGT
Welcome and introduction, Scientific background and context
John Lubel, Monash University, Melbourne, Australia
Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial
Robin Kelley, UCSF, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA
Critical analysis and perspectives
Ian Chau, The Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK
Expert Insights Panel Discussion / Q&A
Faculty and online audience
- Chair: John Lubel, Monash University, Melbourne, Australia
- Robin Kelley, UCSF, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA
- Ian Chau, The Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK
- Su Pin Choo, NCCS - National Cancer Centre Singapore, Singapore
- Chih-Hung Hsu, NTUH - National Taiwan University Hospital, Taipei, Taiwan
The ESMO Virtual Plenaries are freely available to all healthcare professionals working in Oncology.
The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.
